Cardinal Health reports Q3 fiscal 2026 results this morning — and for once, the pre-print setup tilts notably in the bulls' favour.
The most telling move arrived Tuesday, when William Blair initiated coverage with an Outperform rating. That is a meaningful endorsement from a firm willing to put a fresh bullish flag down 48 hours before earnings. It reinforces an already constructive analyst community: twelve of the active recommendations are buys, with no sells on record. The consensus hasn't splintered; it has quietly consolidated on the upside, even as Evercore ISI trimmed its target from $260 to $240 earlier this month, citing a more selective valuation backdrop. Barclays, JPMorgan, Wells Fargo, and Morgan Stanley all lifted targets after the February print, with the cluster of targets sitting in the $240–$258 range. Against a current price of $205.61, that implies roughly 15–20% upside to the Street's midpoint — a meaningful gap that has yet to close.
The factor scores back the constructive picture. CAH ranks in the 94th percentile on analyst recommendation differential — meaning the gap between current ratings and historical norms is unusually wide on the bullish side. The dividend score sits in the 95th percentile, pointing to a distribution track record that income investors prize. EPS momentum is positive, with the 90-day read ranking in the 66th percentile, and the stock's EPS surprise history is roughly neutral at 52. What's absent is a compelling momentum story on price: shares are up just 0.3% for the week and have barely budged in a month, giving the stock a muted feel ahead of the catalyst.
Short positioning carries almost no narrative weight. Short interest runs at 2.5% of the free float — a level that does not mark a crowded or strategically significant short. Borrowing is cheap at 0.43% annualised, and the lending market is loose, with availability well within comfortable bounds. Short interest has drifted roughly 21% higher over the past month, climbing from around 4.8 million shares in late March to 5.9 million now, but it is rising from an extremely low base and does not constitute an aggressive directional bet. Options tell a calmer story too: the put/call ratio is 0.74, fractionally below its 20-day average of 0.77 and clearly below the 52-week high of 1.49 reached when the stock attracted more defensive hedging. In short, neither the borrowing market nor options positioning suggests elevated fear heading into today's print.
The recent earnings record is directly relevant. In February, CAH rose 9.4% the day results landed and extended gains to close the following week up 4.0%. The prior cycle produced a more modest 2.1% single-day gain that rolled into a 8.0% five-day advance. Neither reaction was negative. Whether this string of positive post-print moves continues will depend on whether the Pharma distribution business sustains its volume growth and whether management's guidance holds up against a macro backdrop still unsettled by tariff uncertainty.
Institutional ownership reinforces the stability. Vanguard and BlackRock together hold over 25% of the company. The top fifteen holders all carry meaningful positions, and the latest 13G filings — including Vanguard Capital Management's updated holding, filed today — show passive indices continuing to add quietly. The holder structure is not one that is about to create liquidity events around earnings. What the next few hours will clarify is whether a $205 stock trading 15% below the analyst consensus midpoint finally starts to close that gap, or whether the Street's enthusiasm proves premature.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
